The clinical AI platform for skin, hair and nail disease. It turns a clinical image into a structured, severity-scored assessment in seconds, supporting clinicians at the point of care.
€401K recurring ARR (June 2026) and €604K revenue in 2025 (+49% YoY), built on real clinical usage.
The platform has processed 256K+ clinical reports to date, with monthly volume up ~10x since the Seed round.
A curated overview for prospective investors, updated regularly and anchored to our internal finance records. This is a starting point, not full due diligence; deeper detail is available on request.
The path to a Series A
Legit.Health is at €401K recurring ARR (June 2026). The plan is to grow it to €1M ARR, the milestone that opens a Series A on materially stronger terms, led by an international healthtech / clinical AI fund. The Series A launches when the metrics are met (€1M ARR, FDA pre-submission completed, 2+ multi-year pharma frames), not on a fixed date.
The runway to get there is already funded. Existing investors are doubling down, with Mutua Ventures pro-rata confirmed, on top of a non-dilutive stack of loans and grants. Insiders backing the path is the strongest signal of conviction, and it means new capital funds acceleration, not survival.
Traction
Reading these numbers: ARR is the recurring hospital and insurance layer (66% of 2025 revenue) and the metric we lead on. The full business signed €903K in contract value across 16 deals in 2025: J&J (Psoriasis Phase 3), Boehringer Ingelheim, ICON (Alopecia Phase 3), SESPA, Sanitas/BUPA. Full revenue model →
